FluoSphera expands into the testing of Antibody-Drug-Conjugates (ADCs)

FluoSphera, a Geneva-based leader in systemic drug discovery, is proud to announce its strategic expansion into the testing of Antibody-Drug-Conjugates (ADCs). By deploying new predictive tools based on its proprietary technology, FluoSphera aims to provide ‘first-in-human’ in vitro data on ADCs in development, in order to optimise their properties and increase their clinical success rate.

The major advantage of ADCs lies in their ability to significantly increase the therapeutic index in oncology, by precisely targeting cancer cells while sparing healthy tissue. This precision is based on the combination of the targeted action of monoclonal antibodies and the cytotoxic action of a powerful drug. Unfortunately, clinical results have yet to live up to expectations. This is due to the lack of relevant predictive tools during preclinical evaluations. FluoSphera’s unique technology meets this need by providing reliable predictive data. FluoSphera assesses the tissue selectivity, systemic efficacy and side effects, and so-called ‘bystander’ effects of ADCs, with systemic and human relevance. Thanks to its ‘first-in-human’ in vitro platform, FluoSphera offers a complete profile of human systemic response, enabling developers to focus their efforts on the most promising drug candidates prior to clinical trials.

‘By simulating multiple human organ systems, our platform enables accurate predictions of targeted effects, side effects, as well as systemic impact, well in advance of clinical trials,’ explains Dr. Gregory Segala, Chief Scientific Officer and co-founder of FluoSphera.

‘Our new predictive tools fill a critical need in the CDA field,’ says Dr. Clelia Bourgoint, CEO and co-founder of FluoSphera. ‘We are providing state-of-the-art analytics and highly predictive information to ADC developers, helping them to optimise and select their molecules with confidence. By co-developing ADCs with our partners, we align with common goals, paving the way for more efficient drug development with an increased success rate.’

About FluoSphera

FluoSphera SA’s breakthrough technology fills a critical technology need by completing human systemic relevance at the earliest stages of drug discovery through multiplexed multi-tissue systems. FluoSphera’s technology enables rapid and accurate analysis of human drug responses at the systemic level, even before the first patient is treated. This approach ensures that only the most effective and safest therapies progress to clinical trials, dramatically reducing development times and costs, while providing a brighter future for patients and minimising the need for animal testing.

📸 Gregory Segala (CSO et co-founder FluoSphera), Igor Fisch (Chairman of the board, CEO New Biologix) et Clelia Bourgoint (CEO et co-founder FluoSphera)